Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia (TA393)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 22 June 2016
Bempedoic acid with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia (TA694)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 28 April 2021
Evinacumab for treating homozygous familial hypercholesterolaemia in people 12 years and over (TA1002)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 11 September 2024
Evinacumab for treating homozygous familial hypercholesterolemia in children aged 5 to 11 TS ID 11806Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia (TA394)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 22 June 2016
Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia (TA385)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 24 February 2016
Icosapent ethyl with statin therapy for reducing the risk of cardiovascular events in people with raised triglycerides (TA805)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 13 July 2022
Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia (TA733)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 6 October 2021
Sebelipase alfa for treating lysosomal acid lipase deficiency that is not Wolman disease (terminated appraisal) (TA961)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 28 March 2024
Venglustat for treating gangliosidoses in people 2 years and over ID 6358Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC